Ozempic Muscle Cramps: Electrolytes, Dehydration, and What Helps

Muscle cramps — particularly leg cramps at night or during exercise — are a complaint some people raise after starting Ozempic (semaglutide) or another GLP-1 medication. The honest answer is nuanced: muscle cramps are not a prominent labeled adverse reaction of GLP-1 drugs, and there is no established evidence that these medications cause cramps through a direct pharmacologic mechanism. What the evidence does support is a plausible chain of secondary causes. GLP-1 receptor agonists produce sharp reductions in food and fluid intake, trigger gastrointestinal side effects — including nausea, vomiting, and diarrhea — especially during dose escalation^[1][2], and drive rapid weight loss. Together, these effects can shift the body's fluid balance and electrolyte levels in ways that are well understood to promote muscle cramping. This article explains that chain honestly, covers what helps, and flags the warning signs that need a prescriber or labs.

Does Ozempic cause muscle cramps?

Not directly. Muscle cramps do not appear as a prominent or frequently listed adverse reaction in the FDA labeling for Ozempic or related GLP-1 receptor agonists. In the major semaglutide weight-management trials (STEP program), the adverse events most commonly reported were gastrointestinal: nausea, diarrhea, vomiting, and constipation — not muscle cramps^[1]. Tirzepatide trials showed a similar GI-dominant adverse event profile^[2]. When people on a GLP-1 do experience cramps, the credible explanation is that those gastrointestinal effects, combined with reduced eating and drinking, create downstream conditions — dehydration, electrolyte disturbance, and lean mass loss — that are all established contributors to muscle cramping.

Why GLP-1 medications may indirectly cause muscle cramps

1. Sharply reduced food and fluid intake

The primary purpose of a GLP-1 receptor agonist is to suppress appetite and reduce calorie intake. That suppression is real and powerful — weight loss in STEP-1 averaged 14.9% of body weight at 68 weeks^[1]. But appetite suppression also means people eat and drink considerably less than before. When food intake drops steeply, so does daily intake of key electrolytes: sodium from food, potassium from fruits and vegetables, magnesium from nuts and seeds and whole grains, and calcium from dairy. When fluid intake drops alongside food, mild dehydration can follow. Both electrolyte depletion and dehydration are well-established triggers of skeletal muscle cramping through their effects on membrane excitability and neuromuscular transmission — though a GLP-1-specific randomized trial isolating this mechanism has not been conducted.

2. Gastrointestinal fluid and electrolyte losses during titration

GI adverse events are the most consequential secondary cause. Vomiting and diarrhea — both common during dose escalation on semaglutide^[1] and tirzepatide^[2] — directly deplete fluid and electrolytes. Vomiting depletes gastric acid (rich in hydrogen and chloride) and can lead to metabolic alkalosis; persistent diarrhea depletes sodium, potassium, magnesium, and bicarbonate. Even transient bouts of both during titration can meaningfully lower serum potassium and magnesium. These two electrolytes are closely tied to normal muscle contractility and relaxation: low potassium (hypokalemia) causes weakness and cramping; low magnesium (hypomagnesemia) increases neuromuscular excitability and cramping. Neither effect requires a direct action of the GLP-1 drug — the drug triggers the GI symptoms that drive the losses.

3. Rapid weight loss and early fluid shifts

Rapid weight loss — of the magnitude seen in GLP-1 trials^[1] — involves both fat mass loss and fluid redistribution. Early in caloric restriction, glycogen stores in the liver and muscle are depleted. Glycogen binds water (roughly 3–4 g of water per gram of glycogen), so glycogen depletion releases a meaningful volume of intracellular water along with the sodium and potassium dissolved in it. This early diuresis can transiently lower electrolytes and contribute to cramping in the first weeks of a GLP-1, even before substantial GI side effects develop.

4. Lean mass loss and reduced muscle reserve

GLP-1 medications produce weight loss that includes both fat and lean mass. The lean mass component is a real concern, covered in depth in our GLP-1 lean mass loss guide and our Ozempic leg muscle and loose skin guide. When skeletal muscle volume decreases, the reduced muscle mass may become more vulnerable to cramping under conditions of dehydration or electrolyte stress — though this is a clinical inference rather than a finding from a GLP-1-specific trial. Protein intake and resistance training are the evidence-based interventions to preserve lean mass during GLP-1 therapy^[3], and they may reduce cramping susceptibility indirectly.

Which electrolytes matter most for muscle cramping

Four electrolytes are most closely linked to skeletal muscle cramping. None of these links has been studied in GLP-1-specific randomized trials, but the underlying physiology is well established:

What helps muscle cramps on Ozempic

Because cramps on a GLP-1 are most likely secondary to dehydration, electrolyte depletion, and reduced intake — rather than a direct drug effect — the remedies target those secondary causes. These are general clinical principles rather than GLP-1-specific trial evidence:

• Prioritize hydration, especially during dose escalation. Sip fluids steadily throughout the day even when appetite — and thirst — are suppressed. Pale yellow urine is a reasonable hydration check. If nausea makes drinking difficult, try small sips of electrolyte-containing fluids: broth, diluted juice, or a low-sugar electrolyte drink.
• Eat electrolyte-dense foods at every meal, even smaller ones. Prioritize potassium-rich foods (bananas, avocado, sweet potato, leafy greens), magnesium-rich foods (nuts, seeds, dark chocolate, whole grains), and an adequate sodium intake — a normal-salt diet is appropriate unless your prescriber has directed otherwise. See our guide to electrolytes on a GLP-1 for specific food and supplement guidance.
• Manage GI side effects aggressively. Vomiting and diarrhea are the most direct drivers of electrolyte loss. Eating slowly, eating smaller and lower-fat meals, and discussing anti-nausea strategies and slower titration with your prescriber can reduce the severity and duration of these losses. See our GI side effects guide for the full protocol.
• Maintain protein intake and resistance training. These are the primary tools for preserving lean mass during GLP-1 therapy^[3], which may reduce cramping susceptibility by keeping muscle in better condition. A common clinical target is 1.2–1.6 g of protein per kilogram of body weight per day, though your prescriber or dietitian can tailor this.
• Stretch regularly, especially before sleep. Calf and hamstring stretches before bed are a standard, evidence-supported non-pharmacologic approach to nocturnal leg cramps regardless of cause.
• Ask your prescriber about a metabolic panel. If cramps are frequent or severe, basic labs (sodium, potassium, magnesium, calcium, BUN/creatinine for kidney function) can confirm whether an electrolyte is actually low and guide targeted, safe supplementation. Do not supplement potassium or calcium at high doses without a prescriber's guidance.

When muscle cramps on Ozempic are a red flag

Occasional mild leg cramps are common and generally benign. The following signs suggest a possible electrolyte disturbance serious enough to warrant prompt prescriber contact or evaluation:

• Severe or persistent cramps not relieved by stretching, hydration, or rest, or that worsen over days.
• Muscle weakness or difficulty moving a limb alongside cramps — this pattern can indicate significant hypokalemia or hypomagnesemia.
• Heart palpitations, irregular heartbeat, or chest tightness occurring alongside cramps — low potassium and low magnesium both affect cardiac conduction, and this combination warrants urgent evaluation.
• Numbness, tingling, or muscle twitching around the mouth or extremities — classic signs of hypocalcemia or hypomagnesemia.
• Severe cramps alongside persistent vomiting or diarrhea that prevent you from keeping down fluids — a dehydration and electrolyte emergency that may require intravenous rehydration.
• Dark urine or significantly reduced urine output alongside cramps — possible signs of dehydration severe enough to affect kidney function.

Bottom line

• Muscle cramps are not a well-established direct effect of GLP-1 medications and are not a prominent labeled adverse reaction of Ozempic or semaglutide.
• The credible explanation is secondary: reduced food and fluid intake, GI fluid losses from vomiting and diarrhea during titration^[1][2], and rapid weight loss can deplete electrolytes — especially potassium, magnesium, and sodium — and cause dehydration, both of which promote cramping.
• Lean mass loss during GLP-1 therapy may also reduce muscle resilience, though a direct causal link to cramping has not been established^[3].
• What helps: deliberate hydration, electrolyte-rich foods at every meal, aggressively managing GI side effects, maintaining protein intake and resistance training, and regular stretching.
• Red flags — cramps with palpitations, weakness, irregular heartbeat, or inability to keep down fluids — warrant prompt prescriber contact and a metabolic panel.

Related research

• Best electrolytes for GLP-1 — what sodium, potassium, magnesium, and calcium to prioritize, food sources, and supplement cautions.
• GLP-1 lean mass loss mechanism — why GLP-1 weight loss includes muscle, and the protein and training protocol to limit it.
• Ozempic, leg muscles, and loose skin — the visual and functional consequences of lean mass loss on GLP-1 therapy.
• Ozempic bloating and gas — the GI side effects that drive the fluid and electrolyte losses most linked to cramping.

Important disclaimer. This article is educational and does not constitute medical advice. Muscle cramps during GLP-1 therapy are usually mild and manageable, but persistent or severe cramps — especially alongside palpitations, weakness, or an inability to keep down fluids — require evaluation by a qualified clinician. Do not start, stop, or change the dose of any medication or supplement without consulting your prescriber. Primary sources cited here were verified against the PubMed E-utilities API. Electrolyte and muscle-cramp physiology points are stated as clinical reasoning without citation where no GLP-1-specific RCT exists.